If You Invested in Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. The company’s work centers on cardiorenal and metabolic conditions where excess aldosterone is believed to play a key role in driving elevated blood pressure and organ damage.

The company’s initial product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Lorundrostat is being developed for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as CKD and OSA. According to Mineralys, lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for aldosterone production, and has shown 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro. In clinical studies, lorundrostat has demonstrated a 40–70% reduction in plasma aldosterone concentration in hypertensive participants.

Clinical-stage focus and development programs

Mineralys describes itself as a clinical-stage company, meaning its primary activities relate to the research and clinical development of drug candidates rather than commercial sales. The company reports that it has completed multiple clinical trials of lorundrostat across distinct patient populations with uncontrolled and resistant hypertension and comorbid conditions.

The development program for lorundrostat includes:

• Launch-HTN Phase 3 trial – a global, randomized, double-blind, placebo-controlled trial in adults whose blood pressure remained uncontrolled despite being on two to five antihypertensive medications. Mineralys reports that Launch-HTN met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in systolic blood pressure when lorundrostat was added to existing background therapy, with a favorable safety and tolerability profile.
• Advance-HTN trial – described by the company as a pivotal, registrational trial evaluating lorundrostat for confirmed uncontrolled or resistant hypertension on top of optimized, guideline-based background medications. Mineralys states that Advance-HTN met its primary endpoints and supports the benefit–risk profile of lorundrostat in high-risk patients.
• Transform-HTN open-label extension – an ongoing open-label extension trial that enables participants from earlier studies to continue receiving lorundrostat while Mineralys gathers additional long-term safety and efficacy data.
• Explore-CKD Phase 2 trial – a randomized, double-blind, placebo-controlled crossover trial evaluating 25 mg once-daily lorundrostat in participants with hypertension, reduced kidney function and albuminuria who are on standard-of-care therapy, including renin–angiotensin system blockers and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Mineralys reports that Explore-CKD met its primary endpoint on systolic blood pressure reduction and showed meaningful reductions in proteinuria, as measured by urinary albumin-to-creatinine ratio, with a favorable safety profile.
• Explore-OSA Phase 2 trial – a randomized, double-blind, placebo-controlled crossover trial in overweight or obese adults with moderate-to-severe OSA and hypertension. The trial is designed to evaluate the impact of lorundrostat on apnea-hypopnea index (AHI), blood pressure and nighttime blood pressure. Mineralys has announced completion of enrollment and has indicated plans to report topline results.

Therapeutic focus on dysregulated aldosterone

Across its communications, Mineralys emphasizes dysregulated aldosterone as a key driver of hypertension and related conditions. The company notes that excess aldosterone promotes sodium retention, vascular inflammation and fibrosis, contributing to uncontrolled blood pressure and kidney injury. By selectively inhibiting aldosterone synthase, lorundrostat is intended to address this hormonal pathway directly, rather than blocking aldosterone receptors.

Mineralys highlights that less than half of hypertension patients reach blood pressure goals with currently available medications and that dysregulated aldosterone is believed to be a contributing factor in a substantial portion of hypertensive patients. The company positions lorundrostat’s mechanism as targeting a root cause of hypertension in patient groups that often remain uncontrolled despite multiple therapies.

Target patient populations and comorbidities

The clinical program for lorundrostat spans several high-risk and difficult-to-treat populations. According to Mineralys, Launch-HTN enrolled adults with uncontrolled or treatment-resistant hypertension on two to five background antihypertensive medications, including a substantial proportion of participants who are older, female, Black or African American, or living with obesity. Subgroup analyses presented by the company indicate that lorundrostat produced statistically significant and clinically meaningful blood pressure reductions across these groups, with safety and tolerability consistent with the overall trial population.

In CKD, Mineralys reports that lorundrostat reduced both blood pressure and albuminuria when added to standard-of-care therapy, which included SGLT2 inhibitors. In OSA, the company is evaluating whether targeting aldosterone synthase can affect both sleep-related breathing events and nighttime blood pressure, in a setting where standard positive airway pressure treatment may not sufficiently address blood pressure elevations.

Regulatory and development status

Mineralys has stated that it is pursuing a New Drug Application (NDA) for lorundrostat with the U.S. Food and Drug Administration (FDA). Company disclosures describe Advance-HTN and Launch-HTN as pivotal trials intended to support registration and note that an NDA submission has been planned and, according to one update, filed following completion of multiple positive clinical trials. The company also references pre-NDA interactions with the FDA and ongoing evaluation of lorundrostat in extension and Phase 2 studies to further characterize long-term safety, efficacy and potential use in comorbid conditions.

Corporate background

Mineralys Therapeutics states that it is based in Radnor, Pennsylvania, and that it was founded by Catalys Pacific. The company is listed on Nasdaq under the ticker symbol MLYS. As a clinical-stage biopharmaceutical company, its future performance as described in its forward-looking statements is closely tied to the development, regulatory review and potential approval of lorundrostat.

Risk disclosures and forward-looking information

In its public communications and SEC filings, Mineralys includes extensive forward-looking statements and risk factor discussions. These highlight uncertainties related to clinical trial outcomes, regulatory review, manufacturing, reliance on third parties, and broader macroeconomic and regulatory conditions. The company notes that topline clinical results are based on preliminary analyses and may change with more comprehensive data review, and that prior trial results may not predict future outcomes.

Summary

Overall, Mineralys Therapeutics, Inc. presents itself as a biotechnology company in the professional, scientific and technical services sector, focused on research and development of a single, highly targeted product candidate. Through lorundrostat, the company aims to address uncontrolled and resistant hypertension and related cardiorenal and sleep comorbidities that are associated with dysregulated aldosterone. Its disclosures emphasize selective aldosterone synthase inhibition, multiple completed and ongoing clinical trials, and a development path oriented toward potential regulatory submission and review in the United States.